PARP INHIBITION and OVARIAN CANCER

Leading the Field in Exploiting DNA Repair as a Therapeutic Target

Monday
6 November 2017
16.00 – 17.00

Hall C
Austria Center
Bruno-Kreisky-Platz 1
Vienna, Austria

This educational activity is supported by a grant from Clovis Oncology, Inc.
PARP INHIBITION and OVARIAN CANCER

Leading the Field in Exploiting DNA Repair as a Therapeutic Target

Monday, 6 November 2017 | 16.00 – 17.00 | Hall C, Austria Center

Chair
Nicoletta Colombo, MD
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Faculty
Thomas Helleday, PhD
Karolinska Institute
Stockholm, Sweden

Rebecca Kristeleit, MRCP, PhD
UCL Cancer Institute
University College London
London, United Kingdom

Bradley J. Monk, MD, FACS, FACOG
Arizona Oncology
(US Oncology Network)
University of Arizona College of Medicine-Phoenix
Creighton University School of Medicine at St Joseph’s Hospital
Phoenix, Arizona, United States

Continuing Education
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Agenda
16.00 Welcome and introduction
Nicoletta Colombo, MD

16.02 Introductory quiz
Nicoletta Colombo, MD

16.05 Everything a clinician needs to know about DNA repair and PARP inhibition
Thomas Helleday, PhD

16.20 A new string to the bow in the treatment of advanced ovarian cancer
Bradley J. Monk, MD, FACS, FACOG

16.35 Clinical application of PARP inhibitors: Proactive management of adverse events
Rebecca Kristeleit, MRCP, PhD

16.45 Q & A and faculty discussion

16.53 PARP inhibition and ovarian cancer: Have we convinced you?
Nicoletta Colombo, MD

16.58 prIME Points™
Nicoletta Colombo, MD

17.00 Adjourn

Register online:
prIMEoncology.org/parp-inhibition-ovarian-vienna-2017